Search Results

At CSL, we value workplace health, safety and wellbeing for all of our employees. We employ dedicated Employee, Health & Safety (EHS) managers and teams at all our manufacturing sites.

https://corporateresponsibility.csl.com/workplace/health-and-safety

CSL is committed to the development, manufacture and supply of high quality, safe products that save lives and improve the health and wellbeing of patients with serious diseases.

https://corporateresponsibility.csl.com/safety

CSL is committed to the development, manufacture and supply of high quality, safe products that save lives and improve the health and wellbeing of patients with serious diseases.

https://corporateresponsibility.csl.com/safety/plasma-therapies-and-vaccines

CSL has an Environment, Health, Safety and Sustainability (EHS2) Strategic Plan which ensures its facilities operate to industry and regulatory standards.

https://corporateresponsibility.csl.com/environment

CSL conducts clinical trials in accordance with the current Guideline for Good Clinical Practice (GCP) of the International Conference on Harmonisation (ICH).

https://corporateresponsibility.csl.com/innovation/research-practices/bioethical-issues

CSL is committed to the development, manufacture and supply of high quality, safe products that save lives and improve the health and wellbeing of patients with serious diseases.

https://corporateresponsibility.csl.com/safety/plasma-donations-and-donors

Maintaining constant communication with patient advocacy groups to provide updates on the continued safety and availability of our plasma-derived products for those living with rare and serious conditions.

https://corporateresponsibility.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2020-full.pdf

CSL’s Global CR Committee has overall responsibility for the materiality process and executes a global materiality assessment on a biennial basis. In 2017/18, we concluded our third such assessment and followed the Global Reporting Initiative (GRI) standards of sustainability context, materiality, completeness and stakeholder inclusiveness through our process of identification, review and prioritisation. The application and disclosure of our materiality process against the GRI materiality principle definition was externally assured by Ernst & Young.

https://corporateresponsibility.csl.com/approach/material-topics

CSL regards stakeholder engagement as a foundation of corporate responsibility, and have identified our key stakeholders as patient groups, employees, investors, regulators, suppliers, government, healthcare professionals, plasma donors, business partners and the academic and scientific community.

https://corporateresponsibility.csl.com/approach/stakeholder-engagement

CSL Limited's support for the UN Sustainable Development (SD) Goals

https://corporateresponsibility.csl.com/approach/support-for-the-un-sustainable-development-goals